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Background and purpose: To compare the dosimetric impact of organ and target variations relative to the
applicator for intracavitary brachytherapy by a multicentre analysis with different application techniques
and fractionation schemes.
Material and methods: DVH data from 363 image/contour sets (120 patients, 6 institutions) were included
for 1–6 fractions per patient, with imaging intervals ranging from several hours to 20 days. Variations
between images acquired within one (intra-application) or between consecutive applicator insertions
(inter-application) were evaluated. Dose plans based on a reference MR or CT image series were super-
imposed onto subsequent image sets and D2cm3 for the bladder, rectum and sigmoid and D90 for HR
CTV were recorded.
Results: For the whole sample, the systematic dosimetric variations for all organs at risk, i.e. mean vari-
ations of D2cm3 , were found to be minor (<5%), while random variations, i.e. standard deviations were
found to be high due to large variations in individual cases. The D2cm3 variations (mean ± 1SD) were
0.6 ± 19.5%, 4.1 ± 21.7% and 1.6 ± 26.8%, for the bladder, rectum and sigmoid. For HR CTV, the variations
of D90 were found to be 1.1 ± 13.1% for the whole sample.
Grouping of the results by intra- and inter-application variations showed that random uncertainties for
bladder and sigmoid were 3–7% larger when re-implanting the applicator for individual fractions. No sta-
tistically signiﬁcant differences between the two groups were detected in dosimetric variations for the
HR CTV.
Using 20% uncertainty of physical dose for OAR and 10% for HR CTV, the effects on total treatment dose
for a 4 fraction HDR schedule at clinically relevant dose levels were found to be 4–8 Gy EQD2 for OAR and
3 Gy EQD2 for HR CTV.
Conclusions: Substantial variations occur in fractionated cervix cancer BT with higher impact close to
clinical threshold levels. The treatment approach has to balance uncertainties for individual cases against
the use of repetitive imaging, adaptive planning and dose delivery.
 2013 Elsevier Ireland Ltd. Radiotherapy and Oncology 107 (2013)Open access under CC BY-NC-ND license. 
20–253D image guided brachytherapy (BT) of cervical cancer is
becoming more and more used by centres with access to MRI or
CT imaging facilities for BT planning. This technique allows deliv-
ery of high doses to target structures while doses to organs at risk
can be reduced with the help of 3D images, which provide detailed
information of the anatomical situation and applicator position at
the time of BT planning. (e.g. [1]). Dose-effect relationships for -Radiotherapy and Oncology,
ienna, Währinger Gürtel 18-
(N. Nesvacil).
 CC BY-NC-ND license. cervix cancer BT have been previously reported for the bladder,
rectum and sigmoid [2,3–5] and target [6]. When balancing target
versus OAR dose, the dose levels are usually in the region of a steep
dose-effect curve gradient. Therefore it seems necessary to report
the applied dose with high precision, to identify systematic and
random uncertainties and design treatment schedules and applica-
tion techniques to reduce the uncertainties accordingly.
The present study focuses on the dosimetric impact of anatom-
ical variations of target and organ structures in relation to the
brachytherapy applicator as a ﬁxed reference coordinate system.
The possibility of target and organ motion, i.e. changes in loca-
tion relative to the applicator, variations of shape and/or ﬁlling
N. Nesvacil et al. / Radiotherapy and Oncology 107 (2013) 20–25 21status of organs at risk (OAR), occurring between two individual BT
fractions or within the time of delivery of one fraction, plays an
important role in the assessment of total treatment doses for mul-
ti-fractional brachytherapy treatment and correlations with clini-
cal outcome. This is especially the case when one treatment plan
is used for multiple fractions, or when organ movement occurs in
between imaging and dose delivery.
Dosimetric variations caused by such movement have been re-
ported previously in various treatment planning studies. [7–16].
The majority of these studies focussed on the question whether or
not a single treatment plan may be applied for a multi-fractionated
BT treatment or whether repetitive imaging and, consequently, dose
plan adaptation to modiﬁed OAR anatomy is generally required.
Although it is commonly assumed that the relative position be-
tween the applicator and the target structure remains constant
throughout the whole treatment, and little shrinkage of the target
(HR CTV) will occur during BT, some studies have also analysed
dosimetric changes for HR CTV. For all these studies repetitive 3D
image series were obtained for a number of patients.
The aim of the current study is to compare the dosimetric im-
pact of target and OAR variations by a multicentre analysis based
on pooled data from different institutions with different applica-
tion techniques and fractionation schemes, introducing a common
method for reporting such variations.
As no general recommendations for the reporting of dosimetric
variations caused by relative motions between structures and
applicators during cervix cancer BT exist up to this date, we pro-
pose a general method to report dosimetric uncertainties in per-
centage of planned dose of a reference image set. By doing so, it
becomes possible to compare variations observed at different cen-
tres with different treatment strategies, independent of the abso-
lute dose values obtained. Derived uncertainties could thus be
converted to different treatment schedules and expected ranges
of true delivered doses could be calculated.
The results of our study could help to uncover systematic corre-
lations of time between image acquisitions and dosimetric varia-
tions, and to identify which of the critical organs is affected most
by motions occurring during BT treatment.Materials and methods
Six participants in the GEC ESTRO GYN network performed re-
peated imaging for the analysis of dosimetric changes caused by
anatomical variations during cervix cancer BT. (Medical University
of Vienna (MUV), Mount Vernon Cancer Center (MVCC), University
Medical Center Utrecht (UMCU), Oslo University Hospital (OUH),
Tata Memorial Hospital (TMH), Aarhus University Hospital
(AUH)). These centres were invited to submit their raw data and
to participate in a direct comparison of their individually reported
observations with other institutions.
Table 1 gives an overview of centre-speciﬁc treatment details
and available image data. Details about the imaging protocols,
application techniques, patient selection, contouring andTable 1
Overview of participating centres and the data submitted to this study. Intra-application m
application means that applicators were removed and reinserted between image acquisition
centre’s standard practice are given in the last column.
Centre No. of
patients
Treatment
type
Applicator
type
Time between im
acquisitions
MUV 21 HDR T/R (ic ± is) 12–16 h
MVCC 21 HDR T/R (ic ± is) 5 h (average)
UMCU 9 PDR O (ic + is) 22 h (average)
OUH 11 HDR T/R (ic) 1–20 days
TMH 27 HDR T/R (ic ± is) 7–10 days
AUH 31 PDR T/R (ic) 7 daystreatment planning were reported in the individual publications
listed in Table 1. Four of the participants in the current study
(MUV, UMCU, OUH, AUH) have previously published mono-institu-
tional data for variations due to anatomical changes during BT
treatment. For centres MVCC and TMH, additional unpublished
data were included in this study. Detailed descriptions of their clin-
ical imaging and treatment protocols have been reported by Wills
et al. and Mahantshetty et al. [17,18].
For the present study each centre contributed a set of DVH data
generated with similar workﬂows as described hereafter. An over-
view of the data included in this study is given in Table 1. At every
institution cervix cancer patients were treated with intracavitary
(ic) applicators (tandem/ring (5) or tandem/ovoid (1)) with or
without interstitial (is) needles. Two of the centres treated patients
with PDR BT, four centres used HDR treatment schedules in addi-
tion to EBRT treatment of 45–50 Gy. Data for 120 patients (363 im-
age/contour sets, 308 MRI, 55 CT) were included in this study. For
each patient at least two 3D image sets (MRI (5) or CT (1)) were ac-
quired over the course of BT [19]. In four centres 2–6 image series
were analysed for each patient. Three centres analysed images ob-
tained during the same applicator insertion (intra-application vari-
ations) while the other three analysed DVH parameters based on
images acquired for subsequent applicator insertions (inter-appli-
cation variations). Time intervals between two images for one pa-
tient spanned a large range between 3 and 5 h within one
applicator insertion and up to three weeks between different inser-
tions. For bladder ﬁlling protocols the centres used: constant blad-
der ﬁlling procedures before imaging and before dose delivery,
empty bladders, or open catheters.
HR CTV and OAR were contoured for each image series accord-
ing to GEC ESTRO recommendations [20,21] in ﬁve centres. For
centre OUH, CT based contours of bladder wall and rectal wall
had been included in their original analysis and DVH data included
in the present study are based on these contours. For all centres a
treatment plan generated on the basis of images taken at the
beginning of BT with applicator in place was transferred to consec-
utive images of the same patient and DVH parameters (D90 for tar-
get and D2cm3 for OAR) were reported for HR CTV, bladder, rectum
and sigmoid for all image sets available. The original CT based data
from centre OUH allowed only to investigate minimum doses to 5%
of the bladder and rectum walls, instead of the D2cm3 nowadays
used for OAR dose reporting. Given the volumes of bladder wall
(61.5 ± 21.0 cm3, mean ± 1SD) and rectum wall 51.4 ± 18.8 cm3)
contours these parameters translate to D3cm3 . It was therefore
considered that these parameters were comparable to the D2cm3
used for analysis by other centres, especially since the current
study is focussed on investigating relative changes between DVH
parameters at different time points during BT, rather than compar-
ing absolute DVH values between centres.
For assessment of dosimetric changes due to variations of
shape, position or volume of the delineated structures, the relative
difference between the doses calculated for the reference image
and a subsequent image was calculated as DD = (DiDref)/Dref [%].eans that the applicators stayed in place between two image acquisitions, while inter-
s. References for detailed descriptions of the individual study setups and/or individual
age Image
type
No. of
image sets
Variation type
analysed
References
MRI 84 Intra-application [9,10]
MRI 72 Intra-application [17]
MRI 36 Intra-aplication [11]
CT 55 Inter-application [12]
MRI 54 Inter-application [18]
MRI 62 Inter-application [7,8]
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tions of the relative differences were calculated in order to distin-
guish between systematic and random variations. In order to test
whether a systematic difference in DVH variations can be observed
for intra-application and inter-application scenarios, the mean,
median and standard deviation of the relative differences were cal-
culated for the two groups. Finally the mean, median and standard
deviations (SD) of the relative differences were calculated for the
whole data sample.
The dosimetric variations for delineated structures in this study
are related to relative changes between target or OAR anatomy and
the BT applicators. In the case of intra-application measurements,
the observed variations are related to applicator reconstruction
accuracy and change of location or shape of OAR and targets. For
inter-application measurements, additional differences in applica-
tor positioning relative to target and OAR inﬂuence the dosimetric
variations between consecutive implants.
For testing statistical signiﬁcance of the differences between
uncertainties derived for different groups, a two-tailed t-test (for
systematic variations – mean values) or two-tailed f-test (for ran-
dom variations – SD) was performed. Results were considered to
be statistically signiﬁcant if p < 0.05.
In order to evaluate the clinical importance of the observed
dosimetric uncertainties, typical clinical scenarios for an HDR BT
treatment were simulated to assess the effect of uncertainties
on total accumulated dose. Relevant dose levels (EBRT + BT) were
analysed for OARs and HR CTV, by calculating biologically equiv-
alent doses in 2 Gy fractions (EQD2) according to the linear qua-
dratic model, using a/b = 10 Gy for target and a/b = 3 Gy for OAR
[21]. The dose ranges 60–95 Gy EQD2 and 7095 Gy EQD2 were
simulated in steps of 5 Gy for OARs and targets, respectively, by
varying the physical BT dose and keeping the EBRT dose constant
(45 Gy in 25 fractions). A BT schedule with four HDR fractions
was used.
For each dose level, 40,000 simulations were run. In each sim-
ulation, uncertainties were picked randomly for each brachyther-
apy fraction according to a N(di,r2) distribution where di was the
physical fractional dose and r the standard deviation typical for
intra-application and inter-application variations in target or
OAR. Relevant r levels were chosen according to the results be-
low: 10% and 15% for target, and 20% and 30% for OARs. Each sim-
ulated fractional dose was transformed into EQD2 dose, and
thereafter all fractions were added and summed up with the EBRT
EQD2 dose in order to obtain total EBRT + BT EQD2 dose. Mean
and SD of the 40,000 simulations were evaluated and compared
with the expected dose.Table 2
Observed dosimetric variations for the bladder, rectum, sigmoid/bowel and HR CTV. Relativ
were calculated as DD = (DiDref)/Dref (on reference image and subsequent image number i
means that the dose obtained for image set i was higher than on the reference image.
Structure DD2cm3 between 2 acquisitions [%] (ﬁxed plan, variable an
Intra-application only Inter
Mean SD Mea
Bladder 1.3 ±17.7 0.1
Rectum* 3.8 ±20.5 4.3
Sigmoid 2.3 ±23.5 6.8
DD90 between 2 acquisitions [%] (ﬁxed plan, variable anat
Intra-application only Inter
Mean SD Mea
HR CTV 2.5 ±10.8 0.4
* 3 Extreme outliers (DD2cm3 = 119–240%) were excluded from the overall analysis. Inclu
and 7.7 ± 31.4% for total sample.Results
The relative systematic and random changes of D90 HR CTV and
D2cm3 for OAR between consecutive image acquisitions are reported
as mean and SD uncertainties in percentage of physical dose ob-
tained from the reference images in Table 2. Positive values mean
that the dose obtained from consecutive images was higher than in
the reference image. Results are shown for individual centres
(Fig. 1), as well as for the whole sample and grouped by intra-
and inter-application data (Fig. 1, Table 2).
In one centre (MVCC) three extreme outliers were detected in
the analysis of the data for the rectum. In patients with very low
values of D2cm3 for the ﬁrst MRI, i.e. in cases of small rectum vol-
umes and large distances between organ and applicator at the time
of planning, relative D2cm3 changes between ﬁrst and second MRI of
119–240% were observed. Comparable changes were not detect-
able in any other dataset of the remaining 5 institutions. They
are likely due to a different bowel preparation in these patients.
For this reason, the outliers were excluded from the analysis. Re-
sults for the whole sample, including these data are stated in the
captions of Fig. 1 and Table 2.
The mean ± SD of the relative D2cm3 variations for the whole
sample were 0.6+/19.5%, 4.1 ± 21.7% and 1.6 ± 26.8 for the blad-
der, rectum and sigmoid, respectively. The random uncertainties
(SD) for the inter-application data were found to be signiﬁcantly
larger than the random uncertainties for the intra-application
group for bladder (p = 0.04), sigmoid (p = 0.02) and HR CTV
(p < 0.01). Variances of inter- and intra-application data for the rec-
tum were not signiﬁcantly different from each other.
The differences between random uncertainties (SD) in the inter-
application group were 3–7 percentage points higher than in the
intra-application data, for OARs and target. Observed SD ranges
for random uncertainties of all OARs were 17.7–23.5% and 21.2–
30.2% for intra- and inter-application, respectively. Analysing the
whole sample the observed SD range was 19.5–26.8%. Overall,
the random uncertainties for sigmoid were signiﬁcantly larger than
those for the rectum and bladder (p < 0.01), while variances of the
rectum and bladder did not differ from each other with statistical
signiﬁcance. Mean values, i.e. systematic uncertainties, did not dif-
fer signiﬁcantly between the analysed groups.
The mean ± SD of the relative HR CTV D90 variations for the
whole sample were 1.1 ± 13.1%. Intra-application data showed
lower random (SD) uncertainties (10.8%) than the inter-application
data (15.1%). The statistically signiﬁcant difference (p < 0.01) be-
tween random uncertainties in inter- and intra-applications was
therefore four percentage points. Systematic uncertainties for HRe differences between dose parameters (D2cm3 or D90) from two images/structure sets
= 1–4). Mean and SD of the variations are given in % of physical dose. A positive value
atomy)
-application only Total
n SD Mean SD
±21.2 0.6 ±19.5
±22.8 4.1 ±21.7
±30.2 1.6 ±26.8
omy)
-application only Total
n SD Mean SD
±15.1 1.1 ±13.1
sion would result in 11.2 ± 38.3% (mean ± SD) for rectum for intra-application group
Fig. 1. Results for 6 individual centres. Mean dosimetric variations between consecutive image sets are shown. Error bars indicate SD, median values are shown as horizontal
bars. Open symbols correspond to the intra-application group, ﬁlled symbols to the inter-application group. ⁄3 extreme outliers DD2cm3 ¼ 119 240%were excluded from the
analysis shown in this graph. Inclusion would result in 20.5 ± 54.5% (mean ± SD) for rectum for MVCC, as compared to 0.6 ± 17.4% without outliers.
Fig. 2. Results of the simulation of total treatment dose for EBRT + 4 fractions of
HDR BT. The mean of the total simulated dose in EQD2 is shown for typical expected
dose levels for OAR and HR CTV, assuming typical values for random uncertainties
as observed in our analysis. Expected total doses (without taking into account
dosimetric uncertainties) are indicated by vertical dotted lines. Total EQD2 (with a/
b = 3 Gy for OAR and a/b = 10 Gy for HR CTV) are plotted against the simulated
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found in an intra-fraction data set (MUV).
The largest random uncertainties for D90 HR CTV were found in
a centre with inter-application data acquired one week apart (SD
19.4% (TMH)).
For all investigated DVH parameters no systematic increase or
decrease of the random variation with increasing time between
two image acquisitions was observed.
Based on information of the implant type for each patient avail-
able for two centres in the intra-application group in our analysis,
no signiﬁcant differences between cases with and without intersti-
tial needles were detected.
No systematic differences related to different applicator types
or fractionation schedules (HDR or PDR centres) were detected.
Results of the simulation of total treatment dose in EQD2,
including EBRT and four fractions of HDR BT, and taking into ac-
count dosimetric uncertainties of individual BT fractions are shown
in Fig. 2. Comparison of the expected total doses (EQD2) and the
corresponding means of the simulated total doses, indicates a
small systematic underestimation of total EQD2 if uncertainties
are not taken into account, e.g., for a random uncertainty of 30%
in OAR dose during BT, the mean simulated dose is 3.1 Gy higher
for an expected dose of 95 Gy. For clinically relevant expected total
dose levels for OAR, e.g. 70, 75 and 90 Gy EQD2, observed random
dosimetric uncertainties of 20% and 30% of physical dose between
consecutive image acquisitions lead to random uncertainties (SD)
of the total simulated dose of ±4.3, ±5.2, and ±7.9 Gy EQD2 (for
physical dose SD 20%) and ±6.5, ±7.9 and ±12.0 Gy EQD2 (for phys-
ical dose SD 30%). For HR CTV, at clinically relevant dose values of,
e.g., 85 and 90 Gy EQD2, an observed interfractional dose variation
of 10% leads to simulated random uncertainties of ±2.9 and ±3.3 Gy
while 15% resulted in ±4.4 and ±4.9 Gy, in EQD2.random uncertainty (SD) of the whole treatment dose, in Gy EQD.Discussion
We have presented here the ﬁrst comprehensive overview of
the impact of anatomical variations on dosimetric planning param-
eters in cervix cancer BT in a multicentre setting based on pooled
data. In contrast to BT these effects have been studied extensivelyin the ﬁeld of EBRT, for more than 20 years. For 3D BT only limited
information on this topic was reported until this day [11,12,14].
Compared to dosimetric uncertainties caused by interfractional
variation in EBRT [22], the uncertainties reported in the BT context
are different, due to non-uniform dose distributions in the target
24 Dosimetric impact of inter- and intra-fractional variations in cervix cancer BTarea [23]. Therefore the present detailed analysis of uncertainties
based on a sample of 123 patients has the potential to provide
important information for future optimization of adaptive plan-
ning strategies.
The dosimetric uncertainties for HR CTV presented in the cur-
rent study involve re-imaging, re-reconstruction of applicators
and re-contouring. Therefore, the uncertainties presented in this
paper include inevitably intra- and/or inter-observer uncertainties
of reconstruction and contouring. Dosimetric effects of inter-obser-
ver reconstruction uncertainties have been found to be of the order
<4–5% (SD) [12,23,24] for OARs and target. Inter-observer contour-
ing uncertainties [25] can lead to dosimetric uncertainties of the
order 10% (SD) for HR CTV D90 and 5–10% for OARs [26]. Although
intra-observer variations may be smaller than inter-observer vari-
ations, these data indicate that the intra-application target varia-
tions (SD 11%) found in this study are likely to be dominated by
contouring uncertainties whereas the inter-application variation
(SD 15%) also involves uncertainties due to relation between target
and applicator. However, the intra- and inter-application varia-
tions evaluated for OARs in this paper (SD 20–27%) are clearly
not dominated by reconstruction or contouring uncertainties, and
they originate as such from intra- and inter-application movement
of organs relative to the applicator.
No correlation of observed uncertainties and time between im-
age acquisitions was detected with the method applied in this
study. Therefore the data do not allow drawing any conclusions
about how frequently re-imaging and, consequently, plan adapta-
tion is necessary in general. In order to trace temporal evolution
of anatomical changes during one course of BT it would be neces-
sary to monitor individual patients using a larger number of
images spanning the treatment period, which would be most prof-
itable for assessing total uncertainties of PDR BT.
Kirisits et al. [14] and Mohamed et al. [7] pointed out that
re-planning of individual fractions is advisable for consecutive
applicator insertions when interstitial needles are used. Based
the limited data available in our sample, no signiﬁcant differences
of dosimetric variations for different implant types were detected
for the intra-application setting.
The mean values of observed dosimetric differences indicate
systematic variations while the standard deviation is a measure
for the random uncertainties caused by anatomical variations rel-
ative to the applicator during BT treatment. In cases where the
BT is started early and target shrinkage is still pronounced system-
atic increase in OAR dose may appear because the organs may
move close to the applicator while the target regresses. Kirisits
et al. [14] evaluated inter-application uncertainties by investigat-
ing the impact of using one treatment plan for multiple BT frac-
tions based on structures delineated on MRI taken prior to each
fraction. They reported a mean increase of D90 HR CTV by 6 Gy
EQD2. At the time of that study, BT was delivered during the course
of EBRT, when substantial tumour shrinkage was still in progress.
Mohamed et al. [7] also reported a correlation of observed dosi-
metric variations with reduction of contoured HR CTV volumes be-
tween consecutive PDR applications. Due to the limited target
volume data available for the patients in our present multicentre
study, a detailed analysis of target shrinkage was not feasible.
In case there is no target shrinkage, systematic variations are
expected to be small and not signiﬁcant as no preferred direction
of the shift between structures and applicators are known. This is
true except for changes in bladder shape and volume if no bladder
ﬁlling protocol is applied and bladder volume systematically in-
creases, (as well as for possible systematic increase of rectal vol-
ume due to ﬁlling with air, between image acquisitions within
one applicator insertion). While systematic dosimetric interfrac-
tion uncertainties are therefore expected to be low, large standard
deviations of the observed dosimetric differences indicate that forindividual patients variations might be large and even become
clinically signiﬁcant if planning DVH parameters are close to the
tolerable dose limits.
For the whole data sample from six centres, the derived random
uncertainties were lowest for the bladder (20%) and the rectum
(22%) and highest for sigmoid (27%). This observation ﬁts well with
basic anatomical knowledge of the mobility of the pelvic organs.
The posterior inferior bladder wall and the anterior rectal wall
are relatively ﬁxed in relation to the applicator, whereas sigmoid
loops have more freedom to move independently from the cer-
vix/uterus and the applicator.
Volumetric bladder data were available for three centres. No
signiﬁcant correlation of the change of overall bladder volume with
the change of D2cm3 could be detected.
The largest random dosimetric variations were observed for the
rectum (26%, AUH) and sigmoid (37%, TMH) in centres who analysed
inter-application variations between images acquired at least
1 week apart. Overall, observed random uncertainties (SD) for sig-
moid were found to be signiﬁcantly larger than for the rectum or
bladder. The systematic uncertainties investigated, i. e. mean values
of dosimetric variations, did not differ signiﬁcantly between inter-
and intra- application groups, while random uncertainties were
found to be signiﬁcantly larger for inter-application variations com-
pared to variations occurring within one applicator insertion.
In one centre (MVCC), extreme outliers were detected in the
analysis of dosimetric variations for the rectum (119–240% varia-
tion between two MRI acquisitions). These underlying large
changes in rectal volume and relative position to the applicator
are suspected to be due to a different bowel preparation procedure
used in these patients, as compared to the practice of other centres
participating in this study. The use of a common prospective bowel
preparation protocol might be necessary for a correct interpreta-
tion of such observations in future studies.
Plan adaptation by repetitive CT imaging might be an advisable
strategy, to take into account movement of OAR relative to the
applicator over the course of HDR BT, in centres with limited access
to MRI for planning of all BT fractions. A method for combinedMRI/
CT-based adaptive planning was recently presented by [27].
Our simulations of delivered dose ranges for an example of a
treatment with four fractions of BT support the necessity to try
to minimize delivered doses to critical structures by repetitive
imaging and plan adaptation, especially in patients where planning
DVH parameters were close to the limits. The simulated example
indicated variations of up to ±8 Gy at e.g. bladder doses less than
90 Gy EQD2(a/b = 3) and a typical 20% uncertainty level. Due to
lower total dose, rectum variations are typically lower than
bladder variations: up to ±5 Gy at doses lower than 75 Gy
EQD2(a/b = 3) and 20% uncertainty level. Sigmoid has higher
uncertainty level (e.g. 30%) and therefore variation up to ±8 Gy at
total dose lower than 75 Gy EQD2(a/b = 3). Such OAR uncertainties
of up to ±5–8 Gy could lead to otherwise unexpected side effects.
At clinically relevant dose levels for HR CTV, e.g. 90 Gy EQD2
(a/b = 10), random uncertainties were found to be of the order of
3–5 Gy for the total treatment dose including EBRT and HDR BT.
These deviations have a direct impact on outcome for target and
OAR effects depending on the non-linear dose-effect curves. The
combination of dosimetric uncertainty studies with accurate
dose-effect relationships has to be studied in further detail.
The total effect of interfractional organ and target changes on
the total delivered dose depends on the fractionation schedule of
the BT treatment. The observational material available for this
study did not allow analysing intrafractional variations with high
time resolution. Therefore simulation of the total treatment dose,
taking into account the dosimetric effect of anatomical variations
occurring during different PDR pulse schemes was not possible
based on this material.
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parameter as a representative parameter for the anatomical varia-
tions of OARs and, consequently, their dosimetric impact. Current
clinical evidence points to the D2cm3 being the most important
parameter for OAR morbidity. Future research may show that
intermediate dose levels inﬂuenced by EBRT may be relevant too.
This should be taken into account for the development of a com-
mon protocol for reporting interfraction variations.
By comparison of the relative change of D2cm3 alone, we cannot
take into account that the subvolume of the organ wall receiving
the highest dose by each treated BT fraction might not always be
the same. The method applied to calculate accumulated dose is
therefore based on the assumed ‘‘worst case assumption’’. In order
to assess the cumulative dose in volumes receiving these high
doses, non-rigid registration of OAR structures of different frac-
tions would allow to sum up the doses received by each individual
voxel. Currently there is no solution available for this highly com-
plex problem of non-rigid MRI fusion for cervix cancer BT.
The ﬁndings of this study show substantial variations in frac-
tionated cervix cancer brachytherapy, which have to be taken into
account. The impact of the dosimetric variations on dose-effect de-
pends on the prescribed dose level for a speciﬁc target or OAR.
Variations close to clinical threshold level or in the steep part of
the dose effect-curve have a higher impact on dose effects. Each
centre performing this technique should be aware of the variations
of their individual imaging, planning and dose delivery protocol
and balance uncertainties for individual cases against the use of
repetitive imaging, adaptive treatment planning and dose delivery.Conﬂict of interest
The Department of Radiotherapy at the Medical University of
Vienna receives ﬁnancial and/or equipment support for research
and educational purposes from Nucletron B.V. and Varian Medical
Systems, Inc. CK is a consultant to Nucletron, an Elekta company.
Acknowledgements
This work was supported by the Austrian Science Fund (FWF),
project L562-B19.
The GEC ESTRO network was supported by Varian Corporate
Systems and Nucletron.
Aarhus University Hospital was supported by research Grants
from the European School of Oncology (ESO), Danish Cancer Soci-
ety, Danish Council for Strategic Research, and CIRRO – the Lund-
beck Foundation Centre for Interventional Research in Radiation
Oncology.
References
[1] Pötter R, Georg P, Dimopoulos JC, et al. Clinical outcome of protocol based
image (MRI) guided adaptive brachytherapy combined with 3D conformal
radiotherapy with or without chemotherapy in patients with locally advanced
cervical cancer. Radiother Oncol 2011;100:116–23.
[2] KoomWS, Sohn DK, Kim JY, et al. Computed tomography-based high-dose-rate
intracavitary brachytherapy for uterine cervical cancer: preliminary
demonstration of correlation between dose-volume parameters and rectal
mucosal changes observed by ﬂexible sigmoidoscopy. Int J Radiat Oncol Biol
Phys 2007;68:1446–54.
[3] Georg P, Kirisits C, Goldner G, et al. Correlation of dose-volume parameters,
endoscopic and clinical rectal side effects in cervix cancer patients treated with
deﬁnitive radiotherapy including MRI-based brachytherapy. Radiother Oncol
2009;91:173–80.
[4] Georg P, Lang S, Dimopoulos J, et al. Dose-volume histogram parameters and
late side effects in magnetic resonance image-guided adaptive cervical cancer
brachytherapy. Int J Radiat Oncol Biol Phys 2011;79:356–62.[5] Georg P, Pötter R, Georg D, et al. Dose effect relationship for late side effects of
the rectum and urinary bladder in magnetic resonance image-guided adaptive
cervix cancer brachytherapy. Int J Radiat Oncol Biol Phys 2011;22:22.
[6] Dimopoulos J, Lang S, Kirisits C, et al. Dose-effect relationship for local control
of cervical cancer by magnetic resonance image guided brachytherapy.
Radiother Oncol 2009;93:311–5.
[7] Mohamed SMI, Nielsen SK, Fokdal LU, Lindegaard JC, Tanderup K. Feasibility of
applying one treatment plan for succeeding fractions in image guided
brachytherapy in cervix cancer. Radiother Oncol 2011;99:S56.
[8] Mohamed S. Nielsen S K, Fokdal L U et al, Feasibility of applying a single
treatment plan for both fractions in PDR image guided brachytherapy in cervix
cancer. Radiother Oncol 2013.
[9] Lang S, Georg P, Kirisits C, Dimopoulos J, Kuzucan A, Georg D, et al. Uncertainty
analysis for 3D image based cervix cancer brachytherapy by repeated MRI
examinations: DVH-variations between two HDR fractions within one
applicator insertion. Radiother Oncol 2006;81:S79.
[10] Lang S, Nesvacil N, Kirisits C, et al. Uncertainty analysis for 3D image-based
cervix cancer brachytherapy by repetitive MR imaging: Assessment of DVH-
variations between two HDR fractions within one applicator insertion and
their clinical relevance. Radiother Oncol 2013;107:26–31.
[11] De Leeuw AC, Moerland MA, Nomden C, et al. Applicator reconstruction and
applicator shifts in 3D MR-based PDR brachytherapy of cervical cancer.
Radiother Oncol 2009;93:341–6.
[12] Hellebust T, Dale E, Skjonsberg A, Olsen DR. Inter fraction variations in rectum
and bladder volumes and dose distributions during high dose rate
brachytherapy treatment of the uterine cervix investigated by repetitive CT-
examinations. Radiother Oncol 2001;60:273–80.
[13] Jamema SV, Mahantshetty U, Tanderup K, et al. Inter-application variation of
dose and spatial location of volumes of OARs during MR image based cervix
brachytherapy. Radiother Oncol 2013;107:58–62.
[14] Kirisits C, Lang S, Dimopoulos J, et al. Uncertainties when using only one MRI-
based treatment plan for subsequent high-dose-rate tandem and ring
applications in brachytherapy of cervix cancer. Radiother Oncol
2006;81:269–75.
[15] Beriwal S, Kim H, Coon D, et al. Single magnetic resonance imaging vs
magnetic resonance imaging/computed tomography planning in cervical
cancer brachytherapy. Clin Oncol (R Coll Radiol) 2009;21:483–7.
[16] Anderson C, Lowe G, Wills R, et al. Critical structure movement in cervix
brachytherapy. Radiother Oncol 2013;107:39–45.
[17] Wills R, Lowe G, Inchley D, et al. Applicator reconstruction for HDR cervix
treatment planning using images from 0 35 T open MR scanner. Radiother
Oncol 2010;94:346–52.
[18] Mahantshetty U, Swamidas J, Khanna N, et al. Magnetic resonance image-
based dose volume parameters and clinical outcome with high dose rate
brachytherapy in cervical cancers–a validation of GYN GEC-ESTRO
brachytherapy recommendations. Clin Oncol (R Coll Radiol) 2011;23:376–7.
[19] Dimopoulos JA, Petrow P, Tanderup K, Petric P, Berger D, Kirisits C, et al.
Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group
(IV): basic principles and parameters for MR imaging within the frame of
image based adaptive cervix cancer brachytherapy. Radiother Oncol
2012;103:113–22.
[20] Haie-Meder C, Pötter R, Van Limbergen E, et al. Recommendations from
Gynaecological (GYN) GEC ESTRO Working Group (I): concepts and terms in
3D image-based 3D treatment planning in cervix cancer brachytherapy with
emphasis on MRI assessment of GTV and CTV. Radiother Oncol
2005;74:235–45.
[21] Pötter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from
gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D
image-based treatment planning in cervix cancer brachytherapy-3D dose
volume parameters and aspects of 3D image-based anatomy, radiation
physics, radiobiology. Radiother Oncol 2006;78:67–77.
[22] Andersen ES, Muren LP, Sørensen TS, et al. Bladder dose accumulation based
on a biomechanical deformable image registration algorithm in volumetric
modulated arc therapy for prostate cancer. Phys Med Biol 2012;57:7089–100.
[23] Tanderup K, Pötter R, Lindegaard JC, Berger D, Wambersie A, Kirisits C. PTV
margins should not be used to compensate for uncertainties in 3D image
guided intracavitary brachytherapy. Radiother Oncol 2010;97:495–500.
[24] Hellebust TP, Kirisits C, Berger D, Pérez Calatayud J, De Brabandere M, De
Leeuw A, et al. Recommendations from gynaecological (GYN) GEC-ESTRO
working group: considerations and pitfalls in commissioning and applicator
reconstruction in 3D image-based treatment planning of cervix cancer
brachytherapy. Radiother Oncol 2010;96:153–60.
[25] Petric P, Dimopoulos J, Kirisits C, et al. Inter- and intraobserver variation in HR-
CTV contouring: intercomparison of transverse and paratransverse image
orientation in 3D-MRI assisted cervix cancer brachytherapy. Radiother Oncol
2008;89:164–71.
[26] Hellebust TP, Petric P, Tanderup K, et al. Spatial dosimetric sensitivity analysis
of contouring uncertainties in GYN 3D based brachytherapy. Radiother Oncol
2012;103:34.
[27] Nesvacil N, Pötter R, Sturdza A, et al. Adaptive image guided brachytherapy for
cervical cancer: a combined MRI-/CT-based planning technique with MRI only
at ﬁrst fraction. Radiother Oncol 2013;107:75–81.
